Management of treatment-resistant patients with schizophrenia

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 11, 1996, Pages 26-30

  Marder, Stephen R ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE;

DRUG EFFICACY; DRUG RESEARCH; DRUG SCREENING; HUMAN; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; TREATMENT PLANNING;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0029862819     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. National Institute of Mental Health-Psychopharmacology Service Center Collaborative Study Group: phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry 1964;10:246-261
2. Janicak PG, Davis JM, Preskorn SH, et al. Principles and Practice of Psychopharmacology. Baltimore, Md: Williams & Wilkins; 1993:93-184
3. Kolakowska T, Williams AO, Ardern M, et al. Schizophrenia with good and poor outcome, I: early clinical features, response to neuroleptics and signs of organic dysfunction. Br J Psychiatry 1985;146:229-239
4. Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In: Goodman AG, Rall TW, Nies AS, et al, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York, NY: Pergamon Press; 1990:383-435
5. Keefe RSE, Mohs RC, Silverman JM, et al. Characteristics of kraepelinian schizophrenia and their relation to premorbid sociosexual functioning. In: Angrist B, Schulz SC, eds. The Neuroleptic Nonresponsive Patient: Characterization and Treatment. Washington, DC: American Psychiatric Press; 1990:1-21
6. Weinberger DR, Bigelow LB, Kleinman JE, et al. Cerebral ventricular enlargement in chronic schizophrenia. Arch Gen Psychiatry 1980;37:11-13
7. Crow TJ. Molecular pathology of schizophrenia: more than one disease process? BMJ 1980;280:66-68
8. Kahn RS, Davis KL. New developments in dopamine and schizophrenia. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:1193-1203
9. Van Putten T, Marder SR, Wirshing WC, et al. Neuroleptic plasma levels. Schizophr Bull 1991;17:197-216
10. Marder SR, Hubbard JW, Van Putten T, et al. The pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications. Psychopharmacology 1989;98:433-439
11. Van Putten T, Marder SR. Behavioral toxicity of antipsychotic drugs. J Clin Psychiatry 1987;48(9, suppl):13-19
12. Van Putten T, Marder SR, Mintz J, et al. Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry 1992;149:500-505
13. Thompson C. The use of high-dose antipsychotic medication. Br J Psychiatry 1994;164:448-458
14. Kinon BJ, Kane JM, Johns C, et al. Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull 1993;29:309-314
15. Carman JS, Bigelow LB, Wyatt RJ. Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients. J Clin Psychiatry 1981;42:124-128
16. Small JG, Kellams JJ, Milstein V, et al. A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. Am J Psychiatry 1975;132:1315-1317
17. Wilson WH. Addition of lithium to haloperidol in non-affective, antipsychotic non-responsive schizophrenia: a double-blind, placebo controlled, parallel design clinical trial. Psychopharmacology (Berl) 1993;111:359-366
18. Neppe VM. Carbamazepine in nonresponsive psychosis. J Clin Psychiatry 1988;49(4, suppl):22-28
19. Christison GW, Kirch DG, Wyatt RJ. When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophr Bull 1991;17:217-245
20. Kahn EM, Schulz SC, Perel JM, et al. Change in haloperidol level due to carbamazepine: a complicating medication for schizophrenia. J Clin Psychopharmacology 1990;10:54-57
21. Lingjaerde O. Effect of the benzodiazepine derivative estazolam in patients with auditory hallucinations. Acta Psychiatr Scand 1982;65:339-354
22. Wolkowitz OM, Turetsky N, Reus VI, et al. Benzodiazepine augmentation of neuroleptics in treatment-resistant schizophrenia. Psychopharmacol Bull 1992;28:291-295
23. Fischer-Cornelissen KA, Ferner UJ. An example of European multicenter trials: multispectral analysis of clozapine. Psychopharmacol Bull 1976;12:34-39
24. Kane JM, Honigfeld G, Singer J, et al, and the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison versus chlorpromazine/benztropine. Arch Gen Psychiatry 1988;45:789-796
25. Breier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994;151:20-26
26. Schooler NR, Kane JM, Marder SR, et al. Efficacy of clozapine vs haloperidol in a long term clinical trial: preliminary findings [abstract]. Schizophr Res 1995;15:165
27. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40
28. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
29. Bondolfi G, Bauman P, Patris M, et al. A randomized double-blind trial of risperidone versus clozapine for treatment resistant chronic schizophrenia. In: New Research Program and Abstracts of the 1995 Annual Meeting of the American Psychiatric Association; May 24, 1995; Miami, Fla. Abstract NR485:185
30. Wirshing WC, Ames D, Marder SR, et al. Risperidone in treatment resistant schizophrenia. Presented at the 34th Annual Meeting of the American College of Neuropsychopharmacology; December 11-14, 1995; San Juan, Puerto Rico
31. Carpenter WT Jr, Heinrichs DW, Wagman AMI. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988;145:578-583
32. Siris SG. Adjunctive medication in the maintenance treatment of schizophrenia and its conceptual implications. Br J Psychiatry 1993;163(suppl 22):66-78
33. Bellack AS, Mueser KT. Psychosocial treatment for schizophrenia. Schizophr Bull 1993;19:317-336
34. Lindström LH. Long-term clinical and social outcome studies in schizophrenia in relation to the cognitive and emotional side effects of antipsychotic drugs. Acta Psychiatr Scand Suppl 1994;89(suppl 380):74-76
35. Meltzer HY, Burnett S, Bastani B, et al. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990;41:892-897
36. Moller HJ, Muller H, Borison RL, et al. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients: a re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 1995;245:45-49
37. Lindstrom E, Eriksson B, Hellgren A, et al. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 1995;17:402-412
38. Arvanitis L, Miller BG, Link CGG, et al. Seroquel (ICI-204 636): a novel atypical antipsychotic: efficacy and safety results from two phase II, multicenter, placebo-controlled clinical trials [abstract]. Schizophr Res 1995;15(1,2):142
39. Beasley CM, Tollefson G, Tran P, et al, and the Olanzapine HGAD Study Group. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123
40. Daniel D, Targum S, Zimbroff D, et al. Efficacy, safety, and dose response of three doses of sertindole and three doses of Haldol in schizophrenic patients. Presented at the 34th Annual Meeting of the American College of Neuropsychopharmacology; December 1995; San Juan, Puerto Rico